Results 201 to 210 of about 1,639,688 (287)

Precision Medicine in Neurodegeneration with Brain Iron Accumulation (NBIA) Disorders: An Update on Emerging Treatments

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Neurodegeneration with Brain Iron Accumulation (NBIA) is a heterogeneous group of heritable, mostly recessive, progressive neurodegenerative diseases characterized by iron deposition in the basal ganglia and brainstem. There are no solid global epidemiological data on prevalence and incidence of NBIA subtypes, but registry data and ...
Susanne A. Schneider, Divyani Garg, Vassilena Iankova, Thomas Klopstock   +3 more
wiley   +1 more source

Pharmacologic neuroprotective agents for the treatment of perinatal asphyxia in low-income and lower-middle-income countries: A systematic review and meta-analysis of randomised controlled trials. [PDF]

PLoS One
Ayeni VA, Abdullahi AA, Isah A, Ayamolowo LB, Adeyemi T, Oladimeji MA, Ahwinahwi US, Chukwuike VI, Okeke OP, Abodunrin OR, Akinsolu FT, Sobande OO.   +11 more
europepmc   +1 more source

Recent Advances in Exosome‐Based Nanodelivery Systems for Traumatic Brain Injury Treatment

Med Research, EarlyView.
An overview of functional modification, therapeutic effects, molecular composition, and delivery strategies for exosomes. ABSTRACT Traumatic brain injury (TBI) is a highly heterogeneous neurological condition with extremely high rates of mortality and disability.
Jue Zhu, Weiquan Liao, Ziqi Lian, Mengdan Zhang, Chenxing Wang, Xingjia Zhu, Lin Zhang, Jian Chen, Zhichao Lu, Peipei Gong   +9 more
wiley   +1 more source

Moss Extracts as Natural Neuroprotective Agents: Mitigating LPS-Induced Neuroinflammation and Microglial Activation. [PDF]

Cells
Stojanović TD, Rakić MR, Ćosić MV, Oalđe Pavlović MM, Sabovljević AD, Sabovljević MS, Božić BĐ, Božić Nedeljković BĐ, Vujičić MM, Lunić TM.   +9 more
europepmc   +1 more source

Neuroprotective agents fourth international conference ; [this volume contains the papers from a conference entitled Fourth International Conference on Neuroprotective Agents: Clinical and Experimental Aspects, which was held in Annapolis, Maryland on November 15 - 19, 1998]

, 1999
International Conference on Neuroprotective Agents 1998 Annapolis, Md., Trembly, Bruce   +1 more
core  

Altered Cerebrospinal Fluid Tryptophan–Kynurenine Pathway Metabolism in Multiple System Atrophy

Movement Disorders, EarlyView.
Abstract Background Alterations in tryptophan–kynurenine (TRP‐KYN) metabolism, which is associated with neuroinflammation, remain unclear in multiple system atrophy (MSA). Objective The aim was to investigate cerebrospinal fluid (CSF) TRP metabolites in MSA and their associations with other biomarkers.
Ryunosuke Nagao, Kazuya Kawabata, Yasuaki Mizutani, Sayuri Shima, Akihiro Ueda, Mizuki Ito, Yasuhiro Maeda, Akihiro Mouri, Hirohisa Watanabe   +8 more
wiley   +1 more source

Multi-dimensional data-driven computational drug repurposing strategy for screening novel neuroprotective agents in ischemic stroke. [PDF]

Theranostics
Meng Q, Liu Q, Mi Y, Xu L, Wang F, Mu D, Liu Y, Yang Y, Huang Y, He D, Hou Y.   +10 more
europepmc   +1 more source

COVID‐19 Amplifies Sex‐Specific Dopamine and Glial Responses in a Parkinson's Disease Mouse Model

Movement Disorders, EarlyView.
Abstract Background Exposure to environmental agents, including viral infections, may increase Parkinson's disease (PD) susceptibility, especially in males, but the neurodegenerative risk extent of COVID‐19 remains uncertain. Objectives We investigated the plausible link between severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and
Ifeoluwa Awogbindin, Mélanie Bourque, Marc Morissette, Marie‐Ève Hamelin, Chantal Rhéaume, Jared VanderZwaag, Antonia Landwehr, Disha Patel, Guy Boivin, Marie‐Ève Tremblay, Thérèse Di Paolo   +10 more
wiley   +1 more source

Therapeutic Impact of GLP‐1 Receptor Agonists on Parkinson's Disease: A Scoping Review

Neurology and Clinical Neuroscience, EarlyView.
ABSTRACT No disease‐modifying treatment exists for Parkinson's disease (PD). Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have gained attention as promising candidates for neuroprotection, given documented expression of GLP‐1 receptors within the central nervous system and the contribution of brain insulin resistance to dopaminergic ...
João Pedro Henriques, João Pedro Stringhetta Rahal, Rafael da Cunha Gomes Ribeiro, Enzo Bogucheski Ribeiro Machado, Carlos Antonio Negrato   +4 more
wiley   +1 more source

Carboxychalcones Based on Terephthalaldehydic Acid as Potential Neuroprotective Agents. Synthesis, Computational Study and Biological Evaluation. [PDF]

ACS Omega
Olender D, Skóra B, Kasprzak M, Kujawski J, Sowa-Kasprzak K, Pawełczyk A, Muszalska-Kolos I, Szychowski KA.   +7 more
europepmc   +1 more source